Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial.

Research paper from Europe PMC. Evidence status: source reported.

Published

2012-03-26

Source reference

MED:22452894

DOI

10.1016/s1470-2045(12)70088-8

Jurisdiction

Not assessed

Licence

Bibliographic metadata only; article rights retained

James ND, Sydes MR, Mason MD, Clarke NW, Anderson J, Dearnaley DP, Dwyer J, Jovic G, Ritchie AW, Russell JM, Sanders K, Thalmann GN, Bertelli G, Birtle AJ, O'Sullivan JM, Protheroe A, Sheehan D, Srihari N, Parmar MK, STAMPEDE investigators. · Lancet Oncol · clinical trial, phase iii; clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · Found via: ClinicalTrials.gov result publication

Source: https://europepmc.org/article/MED/22452894. Captured 2026-10-24.

Limitations: Listed by a ClinicalTrials.gov registration as a result publication of that study, and fetched by its PubMed ID. The registry's listing is the sponsor's statement; it does not confirm which data the paper used. Preprints may not be peer reviewed.